The prognostic utility of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in carcinoma of unknown primary (CUP): An experience from a tertiary UK cancer centre
Affiliation
Medical Oncology, The Christie NHS Foundation Trust, ManchesterIssue Date
2022
Metadata
Show full item recordCitation
Scott JA, Peters N, Harman C, Mitchell CL, Conway AM, Cook N. The prognostic utility of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in carcinoma of unknown primary (CUP): An experience from a tertiary UK cancer centre. Annals of Oncology. 2022 Sep;33(7):S774-S. PubMed PMID: WOS:000866211600499.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.634Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.634Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.634